Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the section 2 demo assessing niraparib on the procedure of people with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.
Pharmacy Situations interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Well being Cancer Institute and affiliate professor at Zucker College of Drugs in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual conference on the phase 2 trial of upkeep niraparib in people with phase 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.
During this interview, Frimer reviewed the implications of the section 2 demo examining niraparib on the procedure of clients with stage 3, stage 4, or platinum-delicate recurrent uterine serous carcinoma.
Marina Frimer: So, at this time, we you should not have final results. On the other hand, the study is actively recruiting clients.
Females with uterine serous most cancers normally have large costs of recurrence, and the choices for cure at this time at recurrence are restricted. Success of this trial may possibly transform treatment algorithm to incorporate upkeep therapy with niraparib next platinum-dependent adjuvant chemotherapy.